Meridian Wealth Advisors LLC Buys New Shares in Inhibrx, Inc. (NASDAQ:INBX)

Meridian Wealth Advisors LLC bought a new stake in Inhibrx, Inc. (NASDAQ:INBX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 25,000 shares of the company’s stock, valued at approximately $385,000. Meridian Wealth Advisors LLC owned approximately 0.17% of Inhibrx at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in INBX. HighTower Advisors LLC acquired a new position in shares of Inhibrx during the 4th quarter worth approximately $12,039,000. Bank of New York Mellon Corp acquired a new position in shares of Inhibrx during the 4th quarter worth approximately $792,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Inhibrx during the 4th quarter worth approximately $503,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Inhibrx during the 4th quarter worth approximately $348,000. Finally, Corient Private Wealth LLC acquired a new position in shares of Inhibrx during the 4th quarter worth approximately $316,000. 82.46% of the stock is owned by institutional investors.

Inhibrx Trading Up 1.8 %

Shares of NASDAQ INBX opened at $14.35 on Friday. Inhibrx, Inc. has a 1-year low of $10.80 and a 1-year high of $35.42. The business’s 50 day moving average is $13.27 and its 200-day moving average is $14.64.

Inhibrx (NASDAQ:INBX) last announced its earnings results on Monday, March 17th. The company reported ($3.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.88) by ($0.21). The firm had revenue of $0.10 million during the quarter. On average, sell-side analysts forecast that Inhibrx, Inc. will post 104.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, JMP Securities reissued a “market perform” rating on shares of Inhibrx in a report on Wednesday, January 22nd.

Inhibrx Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.